Literature DB >> 24232697

Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.

Miguel Á Martínez-García1, Javier de Gracia, Monserrat Vendrell Relat, Rosa-Maria Girón, Luis Máiz Carro, David de la Rosa Carrillo, Casilda Olveira.   

Abstract

Bronchiectasis is a multidimensional disease and, therefore, its severity or prognosis cannot be adequately quantified by analysing one single variable. The objective of the present study was to develop a multidimensional score that classifies the severity of bronchiectasis according to its prognosis. This is an observational multicentre study including 819 patients diagnosed with non-cystic fibrosis bronchiectasis using high-resolution computed tomography. 397 subjects were selected at random to construct the score while the remaining 422 were used for its validation. The outcome was 5-year all-cause mortality after radiological diagnosis. A logistic regression analysis was used to select the variables included in the final score. The final seven-point score incorporated five dichotomised variables: forced expiratory volume in 1 s % predicted (F, cut-off 50%, maximum value 2 points); age (A, cut-off 70 years, maximum value 2 points); presence of chronic colonisation by Pseudomonas aeruginosa (C, dichotomic, maximum value 1 point); radiological extension (E, number of lobes affected, cut-off two lobes, maximum value 1 point); and dyspnoea (D, cut-off grade II on the Medical Research Council scale, maximum value 1 point) to construct the FACED score. The validation cohort confirmed the score's validity. We conclude that this easy-to-use multidimensional grading system proved capable of accurately classifying the severity of bronchiectasis according to its prognosis.

Entities:  

Mesh:

Year:  2013        PMID: 24232697     DOI: 10.1183/09031936.00026313

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  99 in total

Review 1.  Medical management of bronchiectasis.

Authors:  Anne E O'Donnell
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Authors:  Gerard Muñoz; Maria Buxó; Javier de Gracia; Casilda Olveira; Miguel Angel Martinez-Garcia; Rosa Giron; Eva Polverino; Antonio Alvarez; Surinder S Birring; Montserrat Vendrell
Journal:  Chron Respir Dis       Date:  2016-02-22       Impact factor: 2.444

Review 3.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 4.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

5.  Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Zhi-Ya Lin; Yan Tang; Hui-Min Li; Zhi-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 6.  Bronchiectasis.

Authors:  Cecile Magis-Escurra; Monique He Reijers
Journal:  BMJ Clin Evid       Date:  2015-02-25

7.  Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.

Authors:  Betina Charvet Machado; Patrícia Santos Jacques; Louise Piva Penteado; Paulo de Tarso Roth Dalcin
Journal:  Lung       Date:  2018-09-25       Impact factor: 2.584

8.  Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.

Authors:  David de la Rosa; Miguel-Angel Martínez-Garcia; Casilda Olveira; Rosa Girón; Luis Máiz; Concepción Prados
Journal:  Chron Respir Dis       Date:  2016-07-07       Impact factor: 2.444

9.  Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis.

Authors:  Meng-Heng Hsieh; Yueh-Fu Fang; Fu-Tsai Chung; Chung-Shu Lee; Yu-Chen Chang; Yuan-Zhang Liu; Cheng-Hsien Wu; Horng-Chyuan Lin
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

10.  Elevated interleukin-6 and bronchiectasis as risk factors for acute exacerbation in patients with tuberculosis-destroyed lung with airflow limitation.

Authors:  Jee Youn Oh; Young Seok Lee; Kyung Hoon Min; Gyu Young Hur; Sung Yong Lee; Kyung Ho Kang; Chin Kook Rhee; Seoung Ju Park; Jae Jeong Shim
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.